Dabidol is the trade name and generic name for Dupliyuzumab Injection, which is usually effective about 1 week after the first dose and is very effective in long-term use. Duprizolizumab Injection is clinically indicated for the treatment of moderate to severe atopic dermatitis in individuals 12 years of age and older who are not well treated with topical medications or for whom the use of topical medications is not recommended. This product needs to be given every two weeks, usually 1 week after the first dose can see the effect, can improve the patient’s itching symptoms, in the adherence to the use of 8 to 16 weeks, can significantly improve the patient’s condition. The adverse reactions of this product include oral herpes, conjunctivitis, headache, eye itching, arthralgia, etc. It is contraindicated for those who are allergic to this product. If the drug is ineffective after 16 weeks of use, discontinuation should be considered. Please adhere to the doctor’s guidance to the hospital medication, do not stop the administration of drugs to avoid recurrence of the disease.